[1]陶碧君,刘建德,王玉洲.LncRNA FOXD3-AS1在恶性肿瘤中的表达、功能及作用机制[J].医学信息,2022,35(10):51-54.[doi:10.3969/j.issn.1006-1959.2022.10.012]
 TAO Bi-jun,LIU Jian-de,WANG Yu-zhou.Expression, Function and Mechanism of LncRNA FOXD3-AS1 in Malignant Tumors[J].Medical Information,2022,35(10):51-54.[doi:10.3969/j.issn.1006-1959.2022.10.012]
点击复制

LncRNA FOXD3-AS1在恶性肿瘤中的表达、功能及作用机制()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年10期
页码:
51-54
栏目:
综述
出版日期:
2022-05-15

文章信息/Info

Title:
Expression, Function and Mechanism of LncRNA FOXD3-AS1 in Malignant Tumors
文章编号:
1006-1959(2022)10-0051-04
作者:
陶碧君刘建德王玉洲
(1.广东医科大学第一临床医学院,广东 湛江 524000;2.暨南大学附属广州红十字会医院内分泌科,广东 广州 510000;3.广东医科大学附属医院肿瘤科,广东 湛江 524000)
Author(s):
TAO Bi-junLIU Jian-deWANG Yu-zhou
(1.First Clinical Medical College,Guangdong Medical University,Zhanjiang 524000,Guangdong,China;2.Department of Endocrine,Guangzhou Red Cross Hospital Affiliated to Jinan University,Guangzhou 510000,Guangdong,China;3.Department of Oncology,Affiliated Ho
关键词:
LncRNA FOXD3-AS1恶性肿瘤生物标志物
Keywords:
LncRNA FOXD3-AS1Malignant tumorBiomarker
分类号:
R730.2
DOI:
10.3969/j.issn.1006-1959.2022.10.012
文献标志码:
A
摘要:
人类细胞中仅有少数经转录而生成的RNAs可作为蛋白质合成的模板,其余的RNA被称为非编码RNAs(ncRNAs),位于编码蛋白的基因之间,其中长度超过200 bp的ncRNAs称为长链非编码RNA(lncRNAs)。LncRNA叉头盒D3反义RNA1(FOXD3-AS1)由4个外显子组成,位于FOXD3启动子上游染色体1p31.3处。LncRNA FOXD3-AS1在很多疾病中存在异常表达,特别是在恶性肿瘤中,且其异常表达与疾病的发生发展有着密切的关系。本文就LncRNA FOXD3-AS1在恶性肿瘤中的表达、功能及其作用机制作一简要综述。
Abstract:
Only a few RNAs produced by transcription in human cells can serve as templates for protein synthesis, the remaining RNAs called non-coding RNAs (ncRNAS), are located between the genes that encode the proteins, ncRNAS which longer than 200 bp are called long non-coding RNAs (LncRNAs). LncRNA forkhead box D3 antisense RNA1 ( FOXD3-AS1 ) consists of four exons, located in the upstream chromosome 1p31.3 of FOXD3 promoter. LncRNA FOXD3-AS1 is abnormally expressed in many diseases, especially in malignant tumors, and its abnormal expression is closely related to the occurrence and development of diseases. This paper reviews the expression, function and mechanism of LncRNA FOXD3-AS1 in malignant tumors.

参考文献/References:

[1]邹小农,贾漫漫,王鑫,等.《2020全球癌症报告》要点解读[J].中国胸心血管外科临床杂志,2021,28(1):11-18.[2]Bashraheel SS,Domling A,Goda SK.Update on targeted cancer therapies,single or in combination,and their fine tuning for precision medicine[J].Biomed Pharmacother,2020,125:110009.[3]Colli LM,Machiela MJ,Zhang H,et al.Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management[J].Cancer Res,2017,77(13):3666-3671.[4]Wu L,Qu X.Cancer biomarker detection:recent achievements and challenges[J].Chem Soc Rev,2015,44(10):2963-2997.[5]Sanchez Calle A,Kawamura Y,Yamamoto Y,et al.Emerging roles of long non-coding RNA in cancer[J].Cancer Sci,2018,109(7):2093-2100.[6]Zhang H,Zhu X,Liu X,et al.Long non-coding RNA FOXD3-AS1 regulates the expression and secretion of IL-25 in nasal epithelial cells to inhibit Th2 type immunoreaction in allergic rhinitis[J].Mol Cell Biochem,2020,473(1-2):239-246.[7]Abel EV,Aplin AE.FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells[J].Cancer Res,2010,70(7):2891-2900.[8]Ji T,Zhang Y,Wang Z,et al.FOXD3-AS1 suppresses the progression of non-small cell lung cancer by regulating miR-150/SRCIN1axis[J].Cancer Biomark,2020,29(3):417-427.[9]Zeng ZL,Zhu HK,He LF,et al.Highly expressed lncRNA FOXD3-AS1 promotes non-small cell lung cancer progression via regulating miR-127-3p/mediator complex subunit 28 axis[J].Eur Rev Med Pharmacol Sci,2020,24(5):2525-2538.[10]Zheng J,Peng B,Zhang Y,et al.FOXD3-AS1 Knockdown Suppresses Hypoxia-Induced Cardiomyocyte Injury by Increasing Cell Survival and Inhibiting Apoptosis via Upregulating Cardioprotective Molecule miR-150-5p In Vitro[J].Front Pharmacol,2020,11:1284.[11]Huang H,Li L,Wen K.Interactions between long non-coding RNAs and RNA-binding proteins in cancer (Review)[J].Oncol Rep,2021,46(6):256.[12]Zhou RS,Zhang EX,Sun QF,et al.Integrated analysis of lncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue[J].BMC Cancer,2019,19(1):779.[13]Li Z,An X,Zhu T,et al.Discovering and Constructing ceRNA-miRNA-Target Gene Regulatory Networks during Anther Development in Maize[J].Int J Mol Sci,2019,20(14):3480.[14]Chen X,Gao J,Yu Y,et al.LncRNA FOXD3-AS1 promotes proliferation,invasion and migration of cutaneous malignant melanoma via regulating miR-325/MAP3K2[J].Biomed Pharmacother,2019,120:109438.[15]Wan N,Yang W,Cheng H,et al.FOXD3-AS1 Contributes to the Progression of Melanoma Via miR-127-3p/FJX1 Axis[J].Cancer Biother Radiopharm,2020,35(8):596-604.[16]Wu Q,Shi M,Meng W,et al.Long noncoding RNA FOXD3-AS1 promotes colon adenocarcinoma progression and functions as a competing endogenous RNA to regulate SIRT1 by sponging miR-135a-5p[J].J Cell Physiol,2019,234(12):21889-21902.[17]Chen Y,Gao H,Li Y.Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-β1/Smads signaling pathway[J].Mol Cell Endocrinol,2020,500:110634.[18]Ma WG,Shi SM,Chen L,et al.SP1-induced lncRNA FOXD3-AS1 contributes to tumorigenesis of cervical cancer by modulating the miR-296-5p/HMGA1 pathway[J].J Cell Biochem,2021,122(2):235-248.[19]Wang Y,Luo W,Wang Y.PARP-1 and its associated nucleases in DNA damage response[J].DNA Repair (Amst),2019,81:102651.[20]Ray Chaudhuri A,Nussenzweig A.The multifaceted roles of PARP1 in DNA repair and chromatin remodelling[J].Nat Rev Mol Cell Biol,2017,18(10):610-621.[21]Zhao X,Li D,Huang D,et al.Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF[J].Mol Ther,2018,26(3):755-773.[22]陈振华.长链非编码RNA FOXD3-AS1在脑胶质瘤中的表达及功能研究[D].上海:第二军医大学,2016.[23]Liu C,Zhang M,Zhao J,et al.LncRNA FOXD3-AS1 Mediates AKT Pathway to Promote Growth and Invasion in Hepatocellular Carcinoma Through Regulating RICTOR[J].Cancer Biother Radiopharm,2020,35(4):292-300.[24]郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.[25]Guan Y,Bhandari A,Xia E,et al.lncRNA FOXD3-AS1 is associated with clinical progression and regulates cell migration and invasion in breast cancer[J].Cell Biochem Funct,2019,37(4):239-244.[26]Masuda S.Pathological examination of breast cancer biomarkers: current status in Japan[J].Breast Cancer,2016,23(4):546-551.[27]Zeng ZL,Zhu HK,He LF,et al.Highly expressed lncRNA FOXD3-AS1 promotes non-small cell lung cancer progression via regulating miR-127-3p/mediator complex subunit 28 axis[J].Eur Rev Med Pharmacol Sci,2020,24(5):2525-2538.[28]张心武,张寅斌,张迪,等.FOXD3-AS1在进展期远端胃癌中的表达及临床意义[J].中国中西医结合消化杂志,2020,28(5):356-359.[29]Chen ZH,Hu HK,Zhang CR,et al.Down-regulation of long non-coding RNA FOXD3 antisense RNA 1 (FOXD3-AS1) inhibits cell proliferation,migration,and invasion in malignant glioma cells[J].Am J Transl Res,2016,8(10):4106-4119.[30]Zhang E,Li C,Xiang Y.LncRNA FOXD3-AS1/miR-135a-5p function in nasopharyngeal carcinoma cells[J].Open Medicine,2020,15(1):1193-1201.

相似文献/References:

[1]袁东方,张刚刚.恶性肿瘤病历主要诊断选择思路分析[J].医学信息,2018,31(07):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
 YUAN Dong-fang,ZHANG Gang-gang.Analysis of Main Diagnostic Options for Malignant Tumor Records[J].Medical Information,2018,31(10):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
[2]张国锐,贾 林,赵 丹,等.老年维持血液透析患者恶性肿瘤发病的相关因素分析[J].医学信息,2022,35(10):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
 ZHANG Guo-rui,JIA Lin,ZHAO Dan,et al.Analysis of Related Factors of Malignant Tumor in Elderly Maintenance Hemodialysis Patients[J].Medical Information,2022,35(10):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
[3]姜天奇,张洪亮.原发性肝癌的中西医治疗现状[J].医学信息,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
 JIANG Tian-qi,ZHANG Hong-liang.Current Status of Treatment of Primary Liver Cancer with Traditional Chinese Medicine and Western Medicine[J].Medical Information,2019,32(10):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
[4]何 静.上皮性卵巢癌化学治疗的研究[J].医学信息,2019,32(18):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
 HE Jing.Chemotherapy of Epithelial Ovarian Cancer[J].Medical Information,2019,32(10):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
[5]梁春玲,杨文珊.消化道恶性肿瘤的临床分析[J].医学信息,2019,32(18):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
 LIANG Chun-ling,YANG Wen-shan.Clinical Analysis of Malignant Tumors of the Digestive Tract[J].Medical Information,2019,32(10):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
[6]陈云娥,李 璠,张子怡,等.营养支持治疗对终末期恶性肿瘤患者临床结局影响的Meta分析[J].医学信息,2019,32(19):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
 CHEN Yun-e,LI Fan,ZHANG Zi-yi,et al.Meta-analysis of Effect of Nutritional Support Therapy on Clinical Outcome of Patients with Terminal-stage Malignant Tumor[J].Medical Information,2019,32(10):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
[7]杜鑫荣.超声造影在肝实质性肿块诊断及鉴别中的临床价值[J].医学信息,2019,32(19):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]
 DU Xin-rong.Clinical Value of Contrast-enhanced Ultrasonography in the Diagnosis and Differential Diagnosis of Liver Mass[J].Medical Information,2019,32(10):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]
[8]易亭伍,邓窈窕,宿向东.恶性肿瘤患者及家属信息需求现状的多中心研究[J].医学信息,2019,32(22):72.[doi:10.3969/j.issn.1006-1959.2019.22.023]
 YI Ting-wu,DENG Yao-tiao,SU Xiang-dong.Multi-center Study on the Status of Information Needs of Patients with Malignant Tumors and their Families[J].Medical Information,2019,32(10):72.[doi:10.3969/j.issn.1006-1959.2019.22.023]
[9]赵博志,赵国林,杨 敏,等.乳腺鳞状细胞癌的临床诊疗研究[J].医学信息,2020,33(03):46.[doi:10.3969/j.issn.1006-1959.2020.03.014]
 ZHAO Bo-zhi,ZHAO Guo-lin,YANG Min,et al.Clinical Diagnosis and Treatment of Squamous Cell Carcinoma of the Breast[J].Medical Information,2020,33(10):46.[doi:10.3969/j.issn.1006-1959.2020.03.014]
[10]吴鑫阳,方明治.中医药治疗恶性肿瘤相关性贫血现状[J].医学信息,2020,33(06):31.[doi:10.3969/j.issn.1006-1959.2020.06.010]
 ZHANG Zhe.Status of Treatment of Malignant Tumor-related Anemia with Traditional Chinese Medicine[J].Medical Information,2020,33(10):31.[doi:10.3969/j.issn.1006-1959.2020.06.010]

更新日期/Last Update: 1900-01-01